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Abstract
Purpose Although the EQ-5D has a long history of use in a wide range of populations, the newer five-level version (EQ-
5D-5L) has not yet had such extensive experience. This systematic review summarizes the available published scientific 
evidence on the psychometric properties of the EQ-5D-5L.
Methods Pre-determined key words and exclusion criteria were used to systematically search publications from 2011 to 
2019. Information on study characteristics and psychometric properties were extracted: specifically, EQ-5D-5L distribution 
(including ceiling and floor), missing values, reliability (test–retest), validity (convergent, known-groups, discriminate) and 
responsiveness (distribution, anchor-based). EQ-5D-5L index value means, ceiling and correlation coefficients (convergent 
validity) were pooled across the studies using random-effects models.
Results Of the 889 identified publications, 99 were included for review, representing 32 countries. Musculoskeletal/ortho-
pedic problems and cancer (n = 8 each) were most often studied. Most papers found missing values (17 of 17 papers) and 
floor effects (43 of 48 papers) to be unproblematic. While the index was found to be reliable (9 of 9 papers), individual 
dimensions exhibited instability over time. Index values and dimensions demonstrated moderate to strong correlations with 
global health measures, other multi-attribute utility instruments, physical/functional health, pain, activities of daily living, 
and clinical/biological measures. The instrument was not correlated with life satisfaction and cognition/communication 
measures. Responsiveness was addressed by 15 studies, finding moderate effect sizes when confined to studied subgroups 
with improvements in health.
Conclusions The EQ-5D-5L exhibits excellent psychometric properties across a broad range of populations, conditions and 
settings. Rigorous exploration of its responsiveness is needed.
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Abbreviations
15D  15 measure of health-related quality 
of life
ADL  Activities of Daily Living
AQoL-8D  Assessment of Quality of Life 
(AQoL)-8D Multi-Attribute Utility 
Instrument
BMI  Body Mass Index
BREAST-Q  Breast surgery-specific patient-
reported outcome measure
DASS-21  Depression, Anxiety and Stress Scale-
21 Items
DEMQOL  Dementia Quality Of Life 
Questionnaire
GAD  Generalized Anxiety Disorder Scale
JOABPEQ  Japanese Orthopedic Associa-
tion (JOA) Back Pain Evaluation 
Questionnaire
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EORTC  European Organization for Research 
and Treatment of Cancer
EQ-VAS  Visual Analog Scale of the Euro-
pean Quality of Life-5 Dimensions 
(EQ-5D)
FIM  Functional Independence Measure
HAL  Hemophilia Activities List
HUI3  Health Utilities Index Mark 3
K-BILD  King’s Brief Interstitial Lung Disease 
Questionnaire
KDQoL  Kidney Disease Quality of Life 
Questionnaire
MBI  Modified Barthel Index
MDS UPDRS  Movement Disorder Society Unified 
Parkinson’s Disease Rating Scale 
(UPDRS)
MRC  Medical Research Council scales for 
muscle strength
mRS  Modified Rankin Scale
NPI-Q  Neuropsychiatric Inventory 
Questionnaire
ODI  Oswestry Disability Index
PACT-Q2  Perception of Anticoagulant Treat-
ment Questionnaire (PACT-Q) Part 2
PHQ-9  Patient Health Questionnaire-9 Items
PEmb-QoL  Pulmonary Embolism Quality Of Life 
Questionnaire
PGA  Patient Global Assessment
QOLIE-31P  Quality of Life in Epilepsy-Patients-
Weighted 31p
PAS-cog  Psychogeriatric Assessment Scale-
Cognitive Impairment
QWB  Quality of Well-Being
SF-6D  Short Form-6 Dimensions
SF-12(v2)  Short Form-12 Items Health Survey; 
v2—version 2 (Subscales: BP – Bod-
ily Pain, GH – General Health, MH 
– Mental Health, PF, RE – Role Emo-
tion, RP – Role Physical, SF – social 
functioning, VT – Vitality, Summary 
Scores: MCS – Mental Component 
Score, PCS – Physical Component 
Score)
SF-36(v2)  Short Form-36 Items Health Survey; 
v2—version 2 (Subscales: BP – Bod-
ily Pain, GH – General Health, MH 
– Mental Health, PF, RE – Role Emo-
tion, RP – Role Physical, SF – social 
functioning, VT – Vitality, Summary 
Scores: MCS – Mental Component 
Score, PCS – Physical Component 
Score)
SWLS  Satisfaction with Life Scale
WHO-5  World Health Organization-5 Well-
Being Index
WHOQoL-BREF  World Health Organization Quality of 
Life Assessment
WOMAC  Western Ontario and McMaster Uni-
versities Osteoarthritis Index
Background
The EQ-5D is a broadly used generic multi-attribute health 
utility instrument. In addition to a thermometer-like visual 
analog scale (VAS) anchored by 0 (worst imaginable health) 
and 100 (best imaginable health), the EQ-5D’s descrip-
tive system comprises five dimensions with one item per 
dimension: mobility (MO), self-care (SC), usual activities 
(UA), pain/discomfort (PD) and anxiety/depression (AD). 
Responses to these items can be converted into a single 
measure of health utility using preference-based (typically 
country-specific) weights. Preference weights are derived 
from preference elicitation studies using hypothetical EQ-5D 
health profiles [1], typically sampling a general population.
Until 2005, respondents could select from three response 
levels of function or symptoms for each dimension (the 
EQ-5D-3L; 3L). However, due to evidence of notable ceil-
ing effects of the EQ-5D-3L in some populations [2–5] and 
concerns regarding the instrument’s sensitivity to certain 
patient-relevant changes [6–10], a five response level version 
of the instrument was developed by the EuroQol group in 
2010 [11, 12]. The five-level version (EQ-5D-5L; 5L) added 
two response levels: one between “no problems” (level 1) 
and “moderate/some problems” (level 2 in 3L, level 3 in 
5L), and another one between “moderate/some problems” 
and “severe problems” (level 3 in 3L, level 5 in 5L). The 
EQ-5D-5L also updated the middle response level with the 
term “moderate” from the EQ-5D-3L’s “some” for the first 
three dimensions, while the most severe response level for 
MO was changed from “confined to bed” to “unable to walk 
about”. Additionally, the instructions for marking overall 
health today on the visual analog scale (VAS) were differ-
ent between the two versions until 2019. The EQ-5D-5L is 
currently available for more than 130 languages [13] and 
has been formally tested against the EQ-5D-3L in numerous 
studies, demonstrating improved psychometric properties 
over the EQ-5D-3L [14]. An interim scoring strategy that 
applies existing EQ-5D-3L preference weights to EQ-5D-5L 
can be used if EQ-5D-5L preference weights for certain pop-
ulations are not yet available [A4].
Although its use has expanded to a wide range of settings 
and research purposes, there is no study reporting a compre-
hensive review of the measurement properties of the EQ-
5D-5L. This review will be informative for researchers inter-
ested in economic evaluation and preference measurement, 
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decision makers, users of EQ-5D-5L as patient-reported out-
come measure for improving health care, and readers who 
need to interpret the findings from studies incorporating the 
EQ-5D-5L. The 5L instrument has now enjoyed over a dec-
ade of use and this paper aims to summarize the existing evi-
dence on the psychometric properties of the EQ-5D-5L. A 
second objective of this review is to identify knowledge gaps 
regarding the psychometric properties of the EQ-5D-5L, and 
to highlight important areas for future research.
Methods
This literature search and review was guided by the PRISMA 
guidance on systematic reviews and meta-analyses [15]. This 
review focuses on the descriptive system of the EQ-5D-5L 
(the five items) as it was not always clear which version of 
the EQ-VAS was used in extracted studies.
Literature search
Four online databases—PUBMED (MEDLINE), PsycINFO, 
Excerpta Medica Database (EMBASE), and the EuroQol 
website—were searched using pre-determined terms: “EQ-
5D,” “EQ-5D-5L,” “5L,” “EuroQol” and “5 Level.” The 
search included publications up to January 2019. Duplicates 
were assessed using author names, titles and journals. Exact 
search strategy and terms can be found in Supplementary 
Table 1.
Two screening phases were conducted: (1) title and 
abstract, and (2) full text. Two researchers experienced 
in psychometric research methods and the EQ-5D instru-
ments (IB and YF) independently screened the publications 
and reached consensus on any disagreements to determine 
inclusion. When consensus could not be reached, two sen-
ior researchers with extensive experience in psychometric 
research, health-related quality of life (HRQoL) measure-
ment and the EQ-5D instrument were consulted for a final 
decision (TK and MFJ).
The a priori exclusion criteria were:
1. does not study humans 18 years or older;
2. publication language is other than German or English;
3. study does not assess the official version of the EQ-
5D-5L or an experimental version of the 5L was used;
4. published prior to 2005 (prior to development of the 5L);
5. not a peer-reviewed primary study, literature review or 
conference paper (conference papers were included but 
other conference proceedings such as presentations or 
posters were excluded); and
6. not evaluating the measurement and psychometric prop-
erties of the EQ-5D-5L.
Data extraction
Publications selected for inclusion were reviewed and data 
entered into pre-determined tables by either YF or IB. Some-
times, values needed to be estimated from available informa-
tion. When information on means and standard deviations 
were not available, but other sufficient data were reported 
(such as range or median), the mean and standard devia-
tions were estimated using recommendations from Wan et al. 
2014 [16]. When multiple studies use the same underlying 
dataset, data was extracted only once (e.g., [A20, A26, 
A31, A36–A38, A49, A53, A77, A79, A96]). General study 
characteristics including sample size, study design, sample 
characteristics and version of EQ-5D-5L were extracted, as 
were information on distributional properties such as means, 
percent reporting best health (“no problems” on dimensions 
or ‘11111’ across the health profile), percent reporting worst 
health (“extreme” or “unable to” on dimensions or ‘55555’ 
across the health profile) and missing values, for dimen-
sions as well as the health profile. Although no guidance for 
level of missing values indicate the feasibility of an instru-
ment, ≤ 5% has been found to be acceptable for multiple 
imputation [17]. Missing values ≤ 5% and floor ≤ 15% are 
considered acceptable [18].
Reliability is the consistency of an instrument, internally 
(extent to which subscale items are interrelated) as well as 
the instrument’s stability across time (whether the instru-
ment produces similar results in stable environments). Inter-
nal consistency is not a relevant psychometric property for 
the EQ-5D instruments and therefore we did not include 
it in this review. Agreement between two applications of 
the instrument over a period of time over which it should 
be stable (test–retest) is usually evaluated using Cohen’s 
Kappa (κ) for categorical items (EQ-5D-5L items) or ICC 
for continuous values (EQ-5D-5L index value), with a level 
of ≥0.8 and ≥0.7 determined as acceptable, respectively 
[19–21]. We relied on the guidance from Cicchetti 1994 [22] 
to define Kappa and ICC: < 0.40 = poor, 0.40–0.59 = fair, 
0.60–0.74 = good, 0.75–1.00 = excellent. Other methods 
such as area under the receiver operating characteristic curve 
(AUROC) were also reported [23, 24].
In general, validity refers to the degree to which a meas-
urement tool captures the underlying construct of interest. 
We extracted all information regarding different forms of 
validity from included publications, the most commonly 
investigated being convergent validity (a specific subtype 
of construct validity), that examines how closely two instru-
ments that are intended to measure the same construct are 
related. This is most often done by testing the correlation 
between the EQ-5D-5L and other measures of health or 
health-related quality of life (including those measuring 
pain, and mental or physical health or HRQoL). Other 
validity results extracted include known-groups validity 
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(examining whether the 5L can distinguish between a priori 
determined groups).
Responsiveness is the ability of an instrument to capture 
true changes (e.g., due to a health intervention) in the con-
struct of interest over time. Some argue that responsiveness 
is a subtype of validity or reliability [25]. Responsiveness 
is of particular importance for the EQ-5D-5L: one of the 
reasons the instrument was created was to address criticisms 
that the EQ-5D-3L was not sufficiently sensitive to change 
[26]. Responsiveness can be specific to population, context, 
and depends on the direction of change in the underlying 
construct [27]. In the case of the EQ-5D-5L, responsiveness 
addresses the question if the index value or individual items 
can detect relevant changes in underlying health. Prelimi-
nary research conducted on experimental five-level versions 
of the EQ-5D found its index value to be sensitive to change. 
Commonly used methods evaluating responsiveness include 
standardized effect size (SES) and/or standardized response 
mean (SRM) [25, 27, 28]. Both standardize the difference in 
means from two measurement points by dividing by standard 
deviation (of the mean or of the change scores). An SES of 
0.2 to 0.3 is considered small, ≈ 0.5 medium and ≥ 0.8 large 
effect sizes [29]. Some studies examined the EQ-5D-5L’s 
ability to detect a change as defined by external criteria, or 
anchor, to estimate minimally important differences (MID) 
or the smallest change in score that is beneficial or relevant 
for patients [27, 28, 30]. The external anchor is usually a 
patient-assessment.
Analysis
Due to the heterogeneity of studies and outcomes included, 
we were only able to summarize three outcomes across stud-
ies: proportion of respondents reporting the best health, 
mean index values, and EQ-5D-5L’s correlations with other 
measures (Spearman’s or Pearson’s Rho). When multiple 
index scores are reported in a study, the most up to date (EQ-
5D-5L as opposed to the interim or ‘crosswalk’) or most 
appropriate (closest to the sampled population) index scores 
were extracted. The signs of correlation coefficients were 
changed if authors had not corrected for the directionality 
of the scales. Subgroup analysis was performed when there 
were at least three studies representing a relevant subgroup.
Data were pooled by means of random-effects models 
using inverse variance weight for pooling. Pooling was based 
on Fisher’s z transformation of correlation coefficients and 
logit transformation of proportions. Microsoft excel was 
used for data extraction, while R was used for data analysis 
[31]. The R package “meta” was used to estimate pooled 
values [32].
Results
We identified 496 papers during the initial search and addi-
tional 397 papers during the updates in 2018 and 2019, of 
which 99 papers were included for review (Fig. 1; reference 
Fig. 1  Literature search and 
inclusion/exclusion results
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list A). These papers included general population (n = 32) 
and patients (n = 58) from 32 countries (see Table 1). The 
country where the most numerous studies were conducted 
was the UK/England (n = 18), while Canada, Germany, 
Singapore and the USA were the locations with the second 
most numerous studies (n = 8 each). The patient groups rep-
resented by the most studies are musculoskeletal/orthopedic 
(n = 8), cancer (n = 8) and lung/respiratory diseases (n = 7). 
The Multi-Instrument Comparison study (MIC) [A20, A26, 
A31, A36–A38, A49, A53, A77, A79, A96] and the study 
that developed a method of deriving 5L interim index val-
ues from 3L value sets [A4, A6, A83] were represented by 
11 and 3 studies, respectively. General characteristics of 
included studies can be found in Supplementary Table 2.  
Distribution properties
Missing values (17 of 17 papers) and most severe health 
state (43 of 48 papers) were under 5% and 15%, respec-
tively, showing the 5L to be feasible and free from floor 
effects (Table 1). Studies with greater than 15% reporting 
the most severe health (in certain dimensions) were those 
studying patients with stroke [A28, A46], spinal cord injury 
[A56], women just after giving birth [A84] and patients with 
chronic illnesses [A83]. These patients were reporting severe 
health impairments in MO, SC, and/or UA. Enough informa-
tion was reported by 48 studies to pool proportion reporting 
the best health state ‘11111,’ which was 23% for patients, 
ranging from 2% (musculoskeletal diseases) to 36% (cancer; 
Fig. 2a). Pooled proportion of over 15% at full health was 
observed for patients with diabetes, cancer, liver diseases, 
kidney diseases and skin diseases. General and healthy 
population studies were 48% and 41% reporting full health, 
respectively (Fig. 2b).
By dimension, proportions reporting “no problems” were 
smallest across the board for stroke, while SC consistently 
had large ceilings except for patients with stroke, diseases 
of the nervous system and diseases of the musculoskeletal 
system (pooled proportion reporting “no problems” in EQ-
5D-5L dimensions can be found in Supplementary Table 3). 
Konnopka and Koenig (2017) also found SC to be most 
problematic in terms of percentage at the ceiling, even for 
those reporting four or more diseases and needing one or 
more hours of daily care [A61].
Index value means could be pooled from 58 publications, 
showing they were generally lower for disease groups than 
healthy populations and lower socio-economic/socio-demo-
graphic groups than higher (Fig. 3a, b).
Reliability
Nine papers addressed test–retest reliability, eight found the 
scale agreement (ICC) excellent and the remaining study 
finding an ICC of 0.7. However, five studies found fair 
agreement on the item level (Cohen’s Kappa) for certain 
dimensions: they tend to be smaller for PD and highest for 
MO (Table 1).
Validity
Studies examining construct validity typically compared 
the EQ-5D-5L to the EQ-5D-3L: the focus has been on the 
response categories as the items themselves were identical. 
As we did not include studies with experimental versions 
of the 5L, most of the earlier studies examining the con-
struct validity of various response options of the 5L have not 
been included. One included study used exploratory factor 
analysis to examine the structure of the EQ-5D-5L, Satis-
faction with Life Scale and MacNew questionnaire [A96]. 
They found MO, SC, UA, and PD to load onto one fac-
tor with other physical health and usual activity items, and 
AD to load onto a second factor including items address-
ing mood, depression, and confidence. Of the five included 
papers addressing content validity, three used qualitative 
methods. Keeley et al. (2013) sampled research profession-
als who found the SC item to be too narrowly defined and 
the UA item to be too broad, while deeming PD and AD as 
the most relevant dimensions related to health-related qual-
ity of life [A7]. Whitehurst et al. (2014) sampled patients 
with spinal cord injuries, who generally found the 5L to be 
relevant for their health problems [A21]. However, some 
found the instrument to lack coverage of specific aspects of 
spinal cord injury. A more recent qualitative study found the 
EQ-5D-5L to lack relevancy for asthma patients except for 
some physical limitations, but also praised the instrument 
for its generic nature [A92].
Craig et al. (2014) found via regression analysis that the 
5L encompasses a slightly larger range of EQ-VAS scores 
from best to worst health state compared to the 3L [A15]. 
Janssen et al. 2018 also investigated the distance between the 
3L and 5L levels using a direct approach asking patients to 
place the labels onto a horizontal VAS scale, finding a larger 
range covered by the 5L [A83].
Convergent validity was assessed by the greatest num-
ber of papers (n = 33), usually examining correlations of 
EQ-5D-5L with other measures of health using Pearson’s 
correlation or Spearman’s Rho rank correlation coefficient. 
Figure 4a–c illustrates pooled correlations of the EQ-5D-5L 
index value with other measures of physical health, men-
tal/social/cognitive health and global health. The strongest 
correlations were observed for multi-attribute utility instru-
ments (pooled rho = 0.756), physical/functional measures 
(pooled rho = 0.582) and pain/discomfort measures (pooled 
rho = 0.595). The EQ-5D-5L index value correlated poorly 
with measures of satisfaction (pooled rho = 0.335) and cog-
nition/communication (pooled rho = 0.259).
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Fig. 2  a Proportion reporting no problems on the EQ-5D-5L profile “11111”: pooled across health conditions. b Proportion reporting no prob-
lems on the EQ-5D-5L profile “11111”: pooled for general and healthy populations
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On a dimension level, the strongest correlation was 
observed for PD and pain measures (pooled rho = 0.636), 
while all items correlated poorly with measures of cog-
nition/communication and vitality/fatigue/sleep. AD was 
the only item to show (moderate) correlation with mental 
(pooled rho = 0.461), emotional and social health items 
(pooled rho = 0.413). Pooled correlation of EQ-5D-5L 
dimensions and other measures of health can be found in 
Supplementary Table 4.
Bhadhuri et al. 2017 examined the EQ-5D-5L’s ability 
to measure spillover effects and found strong correlations 
between EQ-5D-5L scores of family of meningitis survi-
vors and survivors’ social lives (Spearman’s Rho = 0.52, 
0.45), exercise (rho = 0.55, 0.82), and personal health 
(rho = 0.88, 0.95) [A57]. Poor correlations were found 
between carers’ and survivors’ EQ-5D-5L dimensions 
(rho = 0.07 to 0.24), index (rho = 0.19, 0.26), and EQ-VAS 
(rho = 0.22, 0.24).
Table 2 includes information from studies, which exam-
ined validity other than convergent. Generally, the 5L can 
distinguish across disease groups, disease severity, symp-
toms, and related groups, and also across age and educa-
tion. However, it does not consistently distinguish across 
groups differing with certain clinical outcomes (e.g., pres-
ence of deformities in the spine, frequency of medication 
use, gender, use of health services, and marital status.
Responsiveness
Fifteen studies examined whether the EQ-5D-5L captures 
change in health over time. All of these papers included 
SES and/or SRM. Although not reported, the SES could 
be calculated for two papers using reported information 
[A71, A84]. Five assessed results across respondents who 
improved, remained stable or deteriorated over time based 
on an anchor measure [A28, A39, A57, A59, A68, A87]. 
Four papers also reported MID [A46, A50, A71, A85]. 
Two used retrospective items to define change [A50, A71]. 
Table 4 summarizes the responsiveness results—when 
available, the SES and SRM are used for ease of interpret-
ability. The EQ-5D-5L index values typically had moder-
ate effect sizes for improved patients and those expected 
to improve (over the course of medical or therapeutic 
intervention). The largest effect sizes were observed for 
patients days and weeks after giving birth [A84]. Com-
pared to other instruments, the 5L generally performs as 
well or better. Two additional papers addressed dimension-
level changes [A23, A74], both finding the 5L to be more 
sensitive than the 3L. Crick et al. 2018 examined only the 
AD dimension and noted that both the 3L and 5L were 
limited in responsiveness [A74].
Fig. 2  (continued)
662 Quality of Life Research (2021) 30:647–673
1 3
Fig. 3  a EQ-5D-5L index value mean: pooled across health conditions. b EQ-5D-5L index value mean: pooled across education level and 
employment status
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Discussion
The EQ-5D is a generic preference-based health status 
instrument that has enjoyed widespread use since its creation 
in the 1980s [33]. The psychometric properties of the three-
level version have been well established [34–40]. Any reluc-
tance of using the more recently developed five-level version 
might come in part from limited experience and evidence 
for validity, reliability or responsiveness in different popula-
tions [41]. This review summarized published evidence on 
the psychometric properties of the EQ-5D-5L, which has 
been investigated in a broad array of countries, populations 
and contexts in the past decade. No studies found missing 
values to be problematic for the instrument, demonstrating 
feasibility. Test–retest results show potential problems with 
stability over time on an item level, but not at the instrument 
(index score) level. Note that internal consistency is not a 
relevant psychometric property for the EQ-5D-5L since its 
index score is based on a completely different measurement 
framework (as a preference-based measure).
Fig. 3  (continued)
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Fig. 4  a Pooled correlation coefficient for EQ-5D-5L index value 
with other physical health measures. b Pooled correlation coefficient 
for EQ-5D-5L index value with other mental, emotional, cognitive 
and fatigue/vitality health measures. c Pooled correlation coefficient 
for EQ-5D-5L index value with other global health, clinical and non-
health measures
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Fig. 4  (continued)
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Fig. 4  (continued)
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Rather large proportions of respondents reporting the best 
health profile were observed for general population studies 
but less so for patient populations. The EQ-5D was concep-
tualized to measure deviations from full health (or negative 
health) and is more prone to larger ceilings than instruments 
that include positive health dimensions (e.g., the SF-6D). 
Therefore, studies with samples for which impact on the 
functions covered by the EQ-5D-5L (e.g., recovered cancer 
patients, liver disease, diabetes) is less relevant, other dis-
ease-specific instruments should be used in conjunction. On 
the item level, most studies, even those with populations in 
poorer health, reported a substantial ceiling with the dimen-
sion “self-care”, although the ceiling for self-care was low 
for respondents who were expected to have limitations with 
this function (e.g., patients before hip replacement surgery, 
patients shortly after cesarean section, patients with spinal 
cord injury [A21, A24, A84]). These results suggest that 
while most populations may not report problems in “self-
care”, it is relevant for particular patient groups.
Our results overall solidly establish the validity of the 
EQ-5D-5L as supported by observed trends across sub-
groups (pooled means, known-group validity) as well as the 
convergent validity (correlation of items and index to other 
measures of health-related quality of life). Index values as 
well as the dimensions show moderate to strong correlations 
with physical/functional measures, pain, measures of mental 
and emotional health, activities of daily living and clinical/
biological measures as well as with other multi-attribute 
utility measures. On the other hand, the 5L is not found 
to be correlated with satisfaction with life and cognition/
communication measures. Indeed, current efforts investigat-
ing adding dimensions (so-called “bolt-ons”) to the 5L has 
identified cognition as an important dimension missing from 
the EQ-5D [42–44].
Included studies on responsiveness are heterogeneous in 
terms of the population, whether and which anchors were 
used, whether a health intervention was administered, and 
stratification of results across subgroups. This is not a prob-
lem unique to the EQ-5D-5L as, unlike other psychometric 
properties, there is not a set of recommended analyses to 
address responsiveness [25, 30]. Therefore, it is difficult to 
elucidate whether the EQ-5D-5L has problems with sensi-
tivity to change in certain populations or with certain treat-
ments. Despite this limitation, responsiveness is found to 
be acceptable by all included studies. A previous review 
found the EQ-5D-5L to be responsive to half of the condi-
tions included, but found mixed evidence for the other half 
[26]. Responsiveness and sensitivity to changes in health 
is clearly an area that needs further investigation. Future 
studies could benefit from defining what a relevant change 
is for the EQ-5D-5L (MID) and defining appropriate anchor 
measures that can be used across populations (e.g., a level of 
change in EQ-VAS scores or a single self-rated health item). 
Parkin and colleagues (2016) demonstrated the EQ-5D-5L 
distribution to be affected both by the descriptive system 
and the value set applied [45]. Although not a focus of this 
study, the valuation method and applied utility scores are as 
important as the descriptive system when assessing respon-
siveness of index values. It has been shown that choice of 
value set has an impact on utility scores [46–49] and may 
change results of cost-utility analyses [48, 50, 51]. Other 
results show that the effect of value sets on utility scores 
is relatively small [A37, A83]. Due to the heterogeneity of 
studies found in this review, we have insufficient information 
to evaluate how value sets impact responsiveness. Future 
research will benefit from systematically examining respon-
siveness of the descriptive system and how choice of value 
set farther impacts responsiveness.
This review included nearly one hundred studies pub-
lished in the past decade that investigated the psychometric 
properties of the EQ-5D-5L, the majority of which sam-
ple populations from western Europe, OECD countries and 
secondarily, from East Asia. This clearly reflects where the 
EQ-5D-5L is currently used [52]. However, almost a third of 
new user registrations in 2018 come from countries account-
ing for less than 1.5% of total registrations, demonstrating 
widespread as opposed to concentrated use of the instrument 
[52]. For instance, two reviews report rapid uptake of the 
instrument in Eastern Europe [53, 54]. Establishing validity 
in other regions is crucial as the EQ-5D-5L expands in its 
use. Similarly, as the EQ-5D instrument has expanded in its 
application, it would also be important to assess how well 
it performs in particular settings and applications, such as 
used to inform clinical practice, in health services research 
or in health surveillance programs.
Study limitations
A limitation of this study is that studies using experimental 
versions of the EQ-5D-5L were excluded. Early experimen-
tal work on the content validity of the instrument [55–62] 
and investigations of bolt-on items [63] are therefore not 
captured by this review. Similarly, due to the very large num-
ber and range of quality of studies identified, we did not 
include application studies of the EQ-5D-5L which did not 
explicitly address psychometric properties, and therefore are 
missing distributional and perhaps responsiveness informa-
tion that may have been captured by those publications. As 
already discussed, choice of value set and valuation meth-
odology are as important as the descriptive system in the 
case of the EQ-5D. This review does not address valuation 
methods and therefore does not tackle a crucial component 
of the instrument and its index value. A previous review 
of valuation methodology provides valuable information on 
this topic [64].
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Conclusions
The EQ-5D-5L is a reliable and valid generic instrument that 
describes health status which can be applied to a broad range 
of populations and settings. The assessment of responsive-
ness, in particular, needs further and more rigorous explo-
ration. Rather large ceilings persist in general population 
samples, reflecting the conceptualization of the EQ-5D 
instrument, which focuses on limitations in function and 
symptoms, and does not include positive aspects of health 
such as energy or well-being.
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